Dyslipidemia in asthma: Treatable trait, or just a common comorbidity?

Deng, K; Wang, J; Oliver, BG; Wood, LG; Wang, G

Dyslipidemia in asthma: Treatable trait, or just a common comorbidity?

Deng, K Wang, J Oliver, BG Wood, LG Wang, G

Permalink

Publisher:: LIPPINCOTT WILLIAMS & WILKINS
Publication Type:: Journal Article
Citation:: Chin Med J (Engl), 2025, 138, (23), pp. 3097-3114
Issue Date:: 2025-12-05

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Accepted versionAdobe PDF (3.21 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Deng, K
dc.contributor.author	Wang, J
dc.contributor.author	Oliver, BG
dc.contributor.author	Wood, LG
dc.contributor.author	Wang, G
dc.date.accessioned	2026-01-14T03:15:46Z
dc.date.available	2026-01-14T03:15:46Z
dc.date.issued	2025-12-05
dc.identifier.citation	Chin Med J (Engl), 2025, 138, (23), pp. 3097-3114
dc.identifier.issn	0366-6999
dc.identifier.issn	2542-5641
dc.identifier.uri	http://hdl.handle.net/10453/191794
dc.description.abstract	Asthma is a diverse disease that can be categorized into various phenotypes and endotypes, including obesity-re-lated asthma and allergic asthma. "Treatable traits (TTs)" represent a new approach to managing asthma. Asthma accompanied by dyslipidemia would be a distinct asthma phenotype that is becoming increasingly common. Therefore, dyslipidemia can potentially serve as a target for the management of asthma. Nevertheless, it remains highly under-researched compared to other observable traits. Gaining knowledge about the clinical and inflammatory characteristics, underlying mechanisms, and potential therapeutic medications for asthma with dyslipidemia is crucial for its effective management. This review aimed to provide a comprehensive overview of asthma with dyslipidemia, consolidating existing knowledge and ongoing research.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	LIPPINCOTT WILLIAMS & WILKINS
dc.relation.ispartof	Chin Med J (Engl)
dc.relation.isbasedon	10.1097/CM9.0000000000003843
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	1102 Cardiorespiratory Medicine and Haematology, 1199 Other Medical and Health Sciences
dc.subject.classification	General & Internal Medicine
dc.subject.classification	Oncology & Carcinogenesis
dc.subject.classification	3201 Cardiovascular medicine and haematology
dc.subject.mesh	Humans
dc.subject.mesh	Asthma
dc.subject.mesh	Dyslipidemias
dc.subject.mesh	Humans
dc.subject.mesh	Asthma
dc.subject.mesh	Dyslipidemias
dc.title	Dyslipidemia in asthma: Treatable trait, or just a common comorbidity?
dc.type	Journal Article
utslib.citation.volume	138
utslib.location.activity	China
utslib.for	1102 Cardiorespiratory Medicine and Haematology
utslib.for	1199 Other Medical and Health Sciences
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Science
pubs.organisational-group	University of Technology Sydney/Faculty of Science/School of Life Sciences
pubs.organisational-group	University of Technology Sydney/UTS Groups
pubs.organisational-group	University of Technology Sydney/UTS Groups/Centre for Health Technologies (CHT)
utslib.copyright.status	open_access	*
dc.rights.license	This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0). To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.date.updated	2026-01-14T03:15:43Z
pubs.issue	23
pubs.publication-status	Published
pubs.volume	138
utslib.citation.issue	23

Abstract:

Asthma is a diverse disease that can be categorized into various phenotypes and endotypes, including obesity-re-lated asthma and allergic asthma. "Treatable traits (TTs)" represent a new approach to managing asthma. Asthma accompanied by dyslipidemia would be a distinct asthma phenotype that is becoming increasingly common. Therefore, dyslipidemia can potentially serve as a target for the management of asthma. Nevertheless, it remains highly under-researched compared to other observable traits. Gaining knowledge about the clinical and inflammatory characteristics, underlying mechanisms, and potential therapeutic medications for asthma with dyslipidemia is crucial for its effective management. This review aimed to provide a comprehensive overview of asthma with dyslipidemia, consolidating existing knowledge and ongoing research.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/191794